IntelGenx Technologies Corp. and Cary Pharmaceuticals Sign a Definitive Agreement to Develop a Novel Antidepressant

SAINT LAURENT, QUEBEC and GREAT FALLS, VIRGINIA--(Marketwire - November 05, 2007) - IntelGenx Corporation (OTCBB: IGXT) ("IntelGenx" or the "Company") and Cary Pharmaceuticals ("Cary Pharma") today announce the signing of a Definitive Agreement ("Agreement") to jointly develop and commercialize Cary Pharma's oral antidepressant ("CPI-300" or the "Product") using IntelGenx's proprietary oral delivery technology.
MORE ON THIS TOPIC